Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.
You may also be interested in...
Bristol says it's too early to make predictions for future immunotherapy regimens based on new tumor mutation burden analysis of the failed Opdivo Checkmate 026 trial aired at the AACR meeting, but the company plans to fully explore this important biomarker.
Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer
The latest drug development news and highlights from our FDA Performance Tracker.
Failure of Bristol's PD-1 inhibitor Opdivo in first-line lung cancer may open doors for combination use with drugs with immune-activating properties, like prostate cancer drug Xtandi and PARP inhibitor talazoparib.